At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
sunitinib malate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas
In Brief
A Phase 2 clinical trial evaluating sunitinib malate and pharmacological study for Adult Anaplastic Astrocytoma and 7 related conditions. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pineal Gland Astrocytoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJul 2007
Primary CompletionJun 2009
Study CompletionOct 2014
TodayJul 2026
First PostedJul 11, 2007
Enrollment StartJun 1, 2007
Primary CompletionJun 1, 2009
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.0 years ago
Interventions
sunitinib malatedrug
Given orally
pharmacological studyother
Correlative studies